Executive summary

This is a randomized phase II trial compared the radiation-induced grade 3+ lymphopenia (G3+L), which was defined as an absolute lymphocyte count (ALC) nadir of <500 cells/µL, for patients of glioblastoma received PT (n=28) or XRT (n=56), concomitantly with temozolomide.

This study found rates of G3+L were lower in PT vs. XRT (P=0.024)). Sex, baseline ALC, and whole brain V20 were the strongest predictors of G3+L. PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.

Top cancer treatments